References
1. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, et
al. Identification of the cystic fibrosis gene: cloning and
characterization of complementary DNA. Science 1989;245 (4922):1066-73.
2. Rommens JM, Iannuzzi MC, Kerem B, Drumm ML, Melmer G, Dean M, et al.
Identification of the cystic fibrosis gene: chromosome walking and
jumping. Science. 1989;245 (4922):1059-65.
3. Rosenfeld M, Gibson RL, McNamara S, Emerson J, Burns JL, Castile R,
et al. Early pulmonary infection, inflammation, and clinical outcomes in
infants with cystic fibrosis. Pediatr Pulmonol 2001;32 (5):356-66.
4. Sagel SD, Kapsner R, Osberg I, Sontag MK, Accurso FJ. Airway
inflammation in children with cystic fibrosis and healthy children
assessed by sputum induction. Am J Respir Crit Care Med. 2001;164 (8 Pt
1):1425-31.
5. Koch C, Høiby N. Pathogenesis of cystic fibrosis. Lancet.
1993;341(8852):1065-69.
6. Flume PA, Van Devanter DR. State of progress in treating cystic
fibrosis respiratory disease. BMC Med. 2012;10:88.
7. Pressler T.
Review of
recombinant human deoxyribonuclease (rhDNase) in the management of
patients with cystic fibrosis. Biologics 2008;2(4):611-7.
8. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey
BW, et al. Effect of aerosolized recombinant human DNase on
exacerbations of respiratory symptoms and on pulmonary function in
patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med
1994;331(10):637-42.
9. Annual Data Report 2017 Cystic Fibrosis Foundation Patient Registry.
10. ECFSPR Annual Report 2018, Zolin A, Orenti A, Naehrlich L, van Rens
J et al, 2019.
11. De Meyrick J. The Delphi method and health research. Health Educ
2003;103:7-16.
12. Fink A, Kosecoff J, Chassin M, Brook RH. Consensus methods:
characteristics and guidelines for use. American Journal of Public
Health 1984;74 (9):979-983.
13. Black N, Murphy M, Lamping D, McKee M, Sanderson C, Askham J, et al.
Consensus development methods: a review of best practice in creating
clinical guidelines. J Health Serv Res Policy1999;4(4):236-48.
14. Chmiel JF, Konstan MW. Inflammation and anti-inflammatory therapies
for cystic fibrosis. Clin Chest Med. 2007 Jun;28(2):331-46.
15. Konstan MW, VanDevanter DR, Rasouliyan L, Pasta DJ, Yegin A, Morgan
WJ, et al; Scientific Advisory Group; Investigators and Coordinators of
the Epidemiologic Study of Cystic Fibrosis. Trends in the use of routine
therapies in cystic fibrosis: 1995-2005. Pediatr Pulmonol
2010;45(12):1167-72.
16. Konstan MW, Ratjen F. Effect of dornase alfa on inflammation and
lung function: potential role in the early treatment of cystic fibrosis.
J Cyst Fibros 2012;11(2):78-83.
17. Paul K, Rietschel E, Ballmann M, Griese M, Worlitzsch D, Shute J, et
al; Bronchoalveolar Lavage for the Evaluation of Antiinflammatory
Treatment Study Group.
Effect of treatment
with dornase alpha on airway inflammation in patients with cystic
fibrosis. Am J Respir Crit Care Med 2004;169(6):719-25.
18. Yang C, Montgomery M.
Dornase alfa for
cystic fibrosis. Cochrane Database Syst Rev 2018;9 (9):CD001127.
19. Ratjen F, Paul K, van Koningsbruggen S, Breitenstein S, Rietschel E,
Nikolaizik W. DNA concentrations in BAL fluid cystic fibrosis patients
with early lung disease: influence of treatment with dornase alpha.
Pediatr Pulmonol 2005;39(1):1-4.
20. Amin R, Subbarao P, Lou W, Jabar A, Balkovec S, Jensen R, et al. The
effect of dornase alfa on ventilation inhomogeneity in patients with
cystic fibrosis. Eur Respir J 2011;37(4):806-12.
21. Quan JM, Tiddens HA, Sy JP, McKenzie SG, Montgomery MD, Robinson PJ,
et al; Pulmozyme Early Intervention Trial Study Group.
A two-year
randomized, placebo-controlled trial of dornase alfa in young patients
with cystic fibrosis with mild lung function abnormalities. Pulmozyme
Early Intervention Trial Study Group. J Pediatr 2001;139(6):813-20.
22. NICE guideline [NG78]. Avialable at
https://www.nice.org.uk/guidance/ng78.
23. Taylor-Robinson DC, Schechter MS, Smyth RL.
Comparing cystic
fibrosis outcomes across the pond. Thorax 2015;70(3):203-4.
24. Sanders DB, Bittner RC, Rosenfeld M, Redding GJ, Goss CH. Pulmonary
exacerbations are associated with subsequent FEV(1) decline in both
adults and children with cystic fibrosis. Pediatr Pulmonol
2011;46(4):393-400.
25. Britto MT, Kotagal UR, Hornung RW, Atherton HD, Tsevat J, Wilmott
RW. Impact of recent pulmonary exacerbations on quality of life in
patients with cystic fibrosis. Chest 2002; 121 (1):64-72.
26. Wahl AK, Rustoen T, Hanestad BR, Gjengedal E, Moum T. Living with
cystic fibrosis: impact on global quality of life. Heart Lung 2005;34
(5):324-31.
27. Habib AR, Manji J, Wilcox PG, Javer AR, Buxton JA, Quon BS. A
systematic review of factors associated with health-related quality of
life in adolescents and adults with cystic fibrosis. Ann Am Thorac Soc
2015 Mar;12(3):420-8.
28. Quittner AL, Buu A, Messer MS, Modi AC, Watrous M. Development and
validation of the cystic fibrosis questionnaire in the United States: a
health-related quality-of-life measure for cystic fibrosis. Chest
2005;128(4):2347-54.
29. Quittner AL, Buu A, Watrous M, Davis MA. The cystic fibrosis
questionnaire (CFQ): user’s manual. Washington, DC: Cystic Fibrosis
Foundation; 2000.
30. Rubin BK, Ramirez O, King M. Mucus-depleted frog palate as a model
for the study of mucociliary clearance. J Appl Physiol.
1990;69(2):424-9.
31. Heijerman H, Westerman E, Conway S, Touw D, Döring G; consensus
working group.
Inhaled medication
and inhalation devices for lung disease in patients with cystic
fibrosis: A European consensus. J Cyst Fibros 2009;8(5):295-315.
32. Castellani C, Duff AJA, Bell SC, Heijerman HGM, Munck A, Ratjen F,
et a; ECFS best
practice guidelines: the 2018 revision. J Cyst Fibros
2018;17(2):153-78.
33. Konstan MW, Wagener JS, Pasta DJ, Millar SJ, Jacobs JR, Yegin A, et
al. Clinical use of dornase alfa is associated with a slower rate of
FEV1 decline in cystic fibrosis. Pediatr Pulmonol
2011;46(6):545-53.
34. Shak S. Aerosolised recombinant human DNase 1 for the treatment of
cystic fibrosis. Chest 1995;107 (2 Suppl):65S-70S.
35. Wark PA, McDonald V, Jones AP. Nebulised hypertonic saline for
cystic fibrosis. Cochrane Database Syst Rev. 2005; (3):CD001506.
36. Metcalfe C, Lees B, Grieve R, Flather M, Normand C, Thompson S, et
al; Comparison of hypertonic saline and alternate-day or daily
recombinant human deoxyribonuclease in children with cystic fibrosis: a
randomised trial. Lancet 2001;20(358):1316-21.
37. Robinson M, Daviskas E, Ebert S, Baker J, Chan HK, Anderson SD, et
al; The effect of inhaled mannitol on bronchial mucus clearance in CF
patients: a pilot study. Eur Respir J 1999;14 (3):678-85.
38. Daviskas E, Rubin BK. Effect of inhaled dry powder mannitol on mucus
and its clearance. Expert Rev Respir Med 2013;7 (1):65-75.
39. Hurt K, Bilton D.
Inhaled
interventions in cystic fibrosis: mucoactive and antibiotic therapies.
Respiration 2014;88(6):441-8.
40. Bilton D, Stanford G. The expanding armamentarium of drugs to aid
sputum clearance: how should they be used to optimize care? Curr Opin
Pulm Med 2014;20(6):601-6.
41. McKenzie SG, Chowdhury S, Strandvik B, Hodson ME; Investigators of
the Epidemiologic Registry of Cystic Fibrosis. Pediatr Pulmonol
2007;42(10):928-37.
42. Nasr SZ, Kuhns LR, Brown RW, Hurwitz ME, Sanders GM, Strouse PJ. Use
of computerized tomography and chest X-rays in evaluating efficacy of
aerosolized recombinant human DNase in cystic fibrosis patients younger
than age 5 years: a preliminary study. Pediatr Pulmonol
2001;31(5):377-82.
43. ten Berge M, van der Wiel E, Tiddens HAWM, Merkus PJFM, Hop WCJ, de
Jongste JC. DNase in stable cystic fibrosis infants: a pilot study. J
Cyst Fibros 2003;2 (4):183-8.
44. Dentice R, Elkins M.
Timing of dornase
alfa inhalation for cystic fibrosis. Cochrane Database Syst Rev 2018;11
(11):CD007923.
45. Lin AH, Kendrick JG, Wilcox PG, Quon BS.
Patient knowledge
and pulmonary medication adherence in adult patients with cystic
fibrosis. Patient Prefer Adherence. 2017;11:691-8.
46. Modi AC, Lim CS, Yu N, Geller D, Wagner MH, Quittner AL. A
multi-method assessment of treatment adherence for children with cystic
fibrosis. J Cyst Fibros 2006;5(3):177-85.
47. Zindani GN, Streetman DD, Streetman DS, Nasr SZ. Adherence to
treatment in children and adolescent patients with cystic fibrosis. J
Adolesc Health 2006;38(1):13-17.
48. Rouzé H, Viprey M, Allemann S, Dima AL, Caillet P, Denis A, et al;
Adherence to long-term therapies in cystic fibrosis: a French
cross-sectional study linking prescribing, dispensing, and
hospitalization data. Patient Prefer Adherence 2019;13:1497-1510.
49. Macdonald M, Martin-Misener R, Helwig M, Smith LJ, Godfrey CM, et
al; Experiences of adults with cystic fibrosis in adhering to medication
regimens: a qualitative systematic review. JBI Database System Rev
Implement Rep 2016;14(5):258-85.
50. Eakin MN, Riekert KA. The impact of medication adherence on lung
health outcomes in cystic fibrosis. Curr Opin Pulm Med 2013;19
(6):687-91.
51. Eakin MN, Bilderback A, Boyle MP, Mogayzel PJ, Riekert KA.
Longitudinal association between medication adherence and lung health in
people with cystic fibrosis. J Cyst Fibros 2011;10(4):258-64.
52. Arden MA, Drabble S, O’Cathain A, Hutchings M, Wildman M. Adherence
to medication in adults with Cystic Fibrosis: An investigation using
objective adherence data and the Theoretical Domains Framework. Br J
Health Psychol 2019;24(2):357-80.
53. Sawicki GS, Heller KS, Demars N, Robinson WM. Motivating adherence
among adolescents with cystic fibrosis: Youth and parent perspectives.
Pediatric Pulmonol 2015;50(2):127-36.
54. Lomas P.
Enhancing adherence
to inhaled therapies in cystic fibrosis. Ther Adv Respir Dis
2014;8(2):39-47.
55. Miller WR. Motivational interviewing with problem drinkers.
Behavioural Psychotherapy 1983;11:147-172.
56. Duff AJ, Latchford GJ. Motivational interviewing for adherence
problems in cystic fibrosis. Pediatr Pulmonol. 2010;45(3):211-20.
57. Alistair J, Aitken Duff, Latchford GJ.
Motivational
Interviewing for Adherence Problems in Cystic Fibrosis; Evaluation of
Training Healthcare Professionals. J Clin Med Res 2013;5(6):475-80.
58. Gambazza S, Carta F, Brivio A, Colombo C. Aerosol delivery practice
in Italian Cystic Fibrosis centres: a national survey. Arch Physiother
2016;6:1.
59. Conway S, Balfour-Lynn IM, De Rijcke K, Drevinek P, Foweraker J,
Havermans T, et al;
European Cystic
Fibrosis Society Standards of Care: Framework for the Cystic Fibrosis
Centre. J Cyst Fibros 2014;13 Suppl 1:S3-22.